ChristinaGranitz

Cardiologist. Passionate about echocardiography and heart failure

[Ahmed Bennis MD 🫀 @drbennisahmed]

🫀 #HFA2026 | Barcelona, May 9–12 — Most Anticipated Trials #HeartFailure26
7 late-breaking sessions, a record number of submissions, and groundbreaking data expected. Here’s what to watch 👇
🔥 Hottest Trials (1) — May 9
▸ #SUBCUTHFII — Subcutaneous furosemide for early discharge post-HF admission
▸ #REDOXAHF — Restrictive vs. liberal O₂ targets in acute HF
▸ #RePHIRE — AZD3427 (relaxin mimetic) in HF + pulmonary hypertension
▸ #PRAISEMR — Sacubitril-valsartan in HFpEF + secondary mitral regurgitation
▸ #CONDUCTAF — Conduction system vs. biventricular pacing post-AV node ablation
🔬 Innovations in HF Management — May 9
▸ #UFCARE — Ultrafiltration in cardiorenal syndrome type 2
▸ #TRANSFORMHF — Diuretic resistance strategies
▸ #TIMHF3 — Voice-based AI prediction of HF hospitalization
▸ #CARDIOTTRansform — New trial in ATTR-CM
💊 Advances in Cardiomyopathies — May 11
▸ #RESOLVEHCM — Perhexiline in hypertrophic cardiomyopathy
▸ #MAPLEHCM — Dose-dependent effects in HCM
▸ #ATTRibuteCM — Outpatient worsening HF in ATTR-CM
▸ #BHB/HRS1893 — Non-obstructive HCM
🌍 Global Insights — May 11
▸ #THESUSHFII — Acute HF in Africa
▸ #NEDA — Treatment trends & outcomes from Australia
The theme says it all: “Evolution in Heart Failure” 🚀
#HeartFailure2026 #ESCHeartFailure #HFA #Cardiology #CardioTwitter #LateBreakingScience #HFpEF #ATTRCM #HCM #AcuteHeartFailure

[André Zimerman @AndreZimerman]

Today, I had the honor to present PhysioSync-HF as a Late-Breaking Clinical Trial at #ESCCongress.

Key message: In HFrEF and LBBB, conduction system pacing was *inferior* to biventricular pacing for a composite of death, HF events, and LVEF change at 12 months.

[JACC Journals @JACCJournals]

T-TEER improves 1-year survival in patients with intermediate-stage tricuspid regurgitation💡 No benefit seen in early or advanced stages 🚑 Timing of intervention is crucial for optimal outcomes! 🫀 https://t.co/Z2iWRlNKtn

#TEER #Cardiology #vhdTR @PhilippLurz

[John Mandrola, MD @drjohnm]

I support PROFID, not just because it informs Rx for one type of patient but more so for what says for science and the questioning of established practice

If PROFID came to the US, I would be an enthusiastic recruiter of pts

https://t.co/WTlk98kklP

[JACC Journals @JACCJournals]

Anatomic repair of congenitally corrected transposition results in better overall and reintervention-free survival.

Should it be the standard? 🤔

#JACC 📎: https://t.co/7ELqeLKu15

[EJHF Editor-in-Chief @EJHFEiC]

Guideline-directed medical therapy for heart failure in arrhythmia-induced cardiomyopathy with improved left ventricular ejection fraction

https://t.co/4arFIhbErV @ESC_Journals

#EJHF @HanCardiomd @AmrAbdin10 @GiuseppeGalati_

[Ash Paul @pash22]

Abnormalities found on scans in asymptomatic people

[Gregg Fonarow MD @gcfmd]

In HFrEF, lack of therapeutic urgency is:

🌎 Common
💵 Costly
☠️ Deadly

Published in @CircAHA, 5 core "take-home" principles for rapid & intensive #GDMT as a foundational approach

https://t.co/QJZQzgNDjw

@SJGreene_md @JavedButler1

[Victoria Delgado @VDelgadoGarcia]

📡📡Just published BICATOR study showing no effect of atorvastatin in⬇️progression of ascending aorta dilation and aortic valve calcification in BAV. Congratulations to the research group led by @JRodriPalomares and with @EFerrerSistach collaborating from @hgermanstrias 👏👏

[Andrew Sharp @drandrewsharp]

Every single coronary operator on the planet……‘could we soon do STEMI PCI from our beds….’

[European Society of Cardiology @escardio]

Check out the #HFAsnacks with @ppponikowski on a new definition of iron deficiency.

Hosted by @h_arfsten during #HeartFailure2024

#HFA_ESC #ESCTV

[Oung Savly MD FACC FASE FESC FAAP FEACVI 🇰🇭 @OungSavly]

💓 Totally recommended and follow ✅

[Oung Savly MD FACC FASE FESC FAAP FEACVI 🇰🇭 @OungSavly]

6-month-old💓
✅ Straddling Vs Overriding RAVV
✅Rudimentary RV
✅Functionally single ventricle
@ASE360
@alexsfelixecho
@CardioNeo

[Luigi @lpbadano]

tra 2 giorni l'imperdibile webinar del GDS Cardiopatie valvolari sul trattamento delle valvulopatie. Sono le correnti linee guida già obsolete? Rispondono a questa domanda Philippe Pibarot, Rebecca Hahn, Maurice Sarano e Patricia Pellika. What else?

[Saad Ur Rahman @SaadUrRahman55]

Takeaways from #ACC2024. Late breaking trials - take home points @ACCinTouch

1. RELIEVE-HF Trial: In patients with HFrEF and HFpEF, Interatrial Shunt did not show any significant difference in the primary effectiveness endpoint, a composite of all-cause mortality, LVAD/heart transplantation, HF hospitalizations, outpatient worsening HF events.

[John Mandrola, MD @drjohnm]

Should I change my mind about aspirin use for primary prevention?

This is the topic of @Sensible__Med Study of the Week

Thanks for the great discussion this week. And to @johnwmcevoy et al for a great paper

https://t.co/tNgX1zR7hs

[Oung Savly MD FACC FASE FESC FAAP FEACVI 🇰🇭 @OungSavly]

6-month-old. Machinery murmur.

[EHJ Editor-in-Chief @ehj_ed]

Mechanisms, diagnostics and treatment algorithms for cardiac implantable electronic device-related tricuspid regurgitation, an independent clinical entity. Read more in #EHJ.
https://t.co/iR62jF3J2g
#tricuspid #pacemaker #regurgitation #cardiotwitter @ESC_Journals @escardio.

[Irina Akhmedova @Irina67790690]

Large Ventricular Septal Defect.
Higher Pulmonary arterial hypertension.
PAP - 80 mmHg.
T, 18 y.o.

⬇️⬇️⬇️

[MA Garcia Fernandez @MAecocardio]

Espectacular caso de un defecto de Gerbodeven RETIC